Unsustainable Sourcing: Seaweed Innovation Creating a New Market

The global demand for health supplements is booming, with the chondroitin sulfate ingredient alone valued at over $1.7 billion USD in a $7.8 billion supplement market, and projected to grow. However, a troubling truth underpins the chondroitin industry: it is sources from animal bones but 40% is sourced from shark cartilage due to its high chondroitin concentration compared to bovine or synthetic alternatives. This practice sees millions of wild sharks like Blue Sharks and Hammer Heads harvested annually, devastating marine ecosystems and alarming ethically-conscious consumers worldwide.

This critical issue creates a significant market opening. PhycoLife is strategically positioned with a scientifically validated, sustainably farmed seaweed alternative, delivering the important molecular structure found in shark cartilage without ecological devastation.

As consumer demand for ethical, plant-based solutions intensifies, PhycoLife has a clear pathway to capture a substantial share of this expanding multi-billion dollar market, offering potent innovations that heal people and our planet.

We are turning an environmental crisis into a frontier for biotech investment.

Did you miss the Investor Q&A?  Watch it here

Integrated Innovation, Creation, and Control

Building on our proven model highlighted previously, PhycoLife's core strength lies in our comprehensive mastery of the entire seaweed value chain. We are not simply product sellers; we are fundamental creators, meticulously managing every stage from proprietary indoor marine cultivation and advanced bio-refining to the formulation of market-leading health products that meet stringent food and medical standards.

This end-to-end Australian-based supply chain control is crucial for our innovation, ensuring premium quality, traceability, and the rapid development of novel solutions.

Our commitment extends deeply into pioneering research and development. PhycoLife functions as a deep-tech innovation engine, actively driving glycobiology and marine biotechnology advancements that could lead to opportunities beyond what the market can see.

This R&D focus generates significant intellectual property, which underpins our unique ingredients like Phyaluronic™ (SXRG84) and our next-generation SeaFibre supplements. This integrated system of sustainable cultivation, controlled processing, and frontier science allows us to consistently deliver our diverse range of clinically validated supplements, bioactive skincare, and award-winning functional foods to a discerning market.

$1m in Revenue FY25 + 60% Customer Retention

PhycoLife has achieved significant milestones, validating our business model and strong market demand. We proudly surpassed $1 million in revenue in FY25, driven by 160% annual sales growth and revenue tripling in the last six months alone. Our product efficacy and brand loyalty are confirmed by an exceptional ~60% customer retention rate and a customer base that more than doubled in the past year.

Operationally, we pioneered Australia’s first fully integrated seaweed value chain—from proprietary indoor cultivation and biorefining to creating novel ingredients like Phyaluronic™ that are clinically tested and that meet food grade standards. Our science is robust, with two pioneering human clinical trials published, leading to strong research partnerships across 4 universities and with numerous industry partners. This innovation and market leadership have garnered significant industry recognition, including multiple Australian Food Awards, "Most Innovative Protein Source" (International Food Expo London 2025), and prominent features in Forbes, BBC, and ABC.

These accomplishments showcase a de-risked, revenue-generating business primed for accelerated scaling.

Investor rewards

We want our shareholders to be as big fans of our products as we are, and to reap the health rewards. We are proud off offer a range of rewards for investment in the crowd equity campaign as follows: